CALL US: 206.533.3854
CALL US  206.533.3854
CDC image of Perinatal Hepatitis C;  public domain:  https://www.cdc.gov/nchhstp/newsroom/2016/hcv-perinatal.html

Failure to Meet Enablement Requirement Gives Patent Priority to Other Party

Patent applicants
must show how invention’s made —
that’s “enablement”

The Federal Circuit has affirmed a decision of the Patent Trial and Appeal Board (PTAB) involving the priority of inventions for a hepatitis C treatment.

The case of Storer et al. v. Clark involves methods of treating hepatitis C by administering compounds with a specific chemical structure.

Richard Storer and other investors were issued a US Patent patent for the treatment based on an application filed in June, 2003.  The application also claimed priority to a provisional application filed in 2002.

Another application for the treatment, by Jeremy Clark, was filed in 2007, with a priority claimed to a provisional application filed in May, 2003.

Both applications were filed before the effective date of the America Invents Act, which abolished the old “first-to-invent” interference rule in favor of the new “first-to-file” rule.  So the older rule applied to this case.

Storer was initially declared the senior party based on the 2002 provisional application.

However, Clark challenged this, arguing that the provisional application didn’t “enable” compounds having specific characteristics.

Storer replied that the compounds were generically disclosed in his provisional application.

The PTAB found that Storer was not entitled to take priority based on the 2002 provisional application and awarded priority to Clark.

A patent application must include

a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.

According to the Federal Circuit,

The enablement requirement is met where one skilled in the art, having read the specification, could practice the invention without ‘undue experimentation.’

When an issue is priority based on the specification, the earlier patent application must meet the enablement requirement.

The Federal Circuit found that the Storer provisional application didn’t describe synthesis of the compounds at issue, because Storer only described general approaches to synthesizing.

The court thus concluded that “a high amount of experimentation is necessary to synthesize” the target compound and thus that Storer’s application failed the enablement requirement.

Related Articles

Patent Office Says Coding Error Affected PTA Determinations

The US Patent and Trademark Office (USPTO) has announced that a recent update to its software “introduced a coding error into the patent term adjustment ...
Read More

Federal Circuit Vacates Ruling for Failing to Apply Presumption of Patent Validity

The Federal Circuit has vacated a District of Delaware ruling in a patent case which found that patent claims asserted by Astellas Pharma were invalid ...
Read More

Anti-AI “NO FAKES” Act Moves Forward in Congress

Several Representatives, including both Democrats and Republicans, have introduced the “Nurture Originals, Foster Art, and Keep Entertainment Safe Act of 2024’’ (NO FAKES Act) in the ...
Read More

Let's work together.

Contact us to set up a meeting with an attorney or team member.

Stay Informed

Sign up to receive Patent Poetry—a monthly roundup of key IP issues in our signature haiku format. Four articles (only 68 syllables); zero hassle.

SECTORS

HIGH
TECHNOLOGY

Artificial Intelligence

Blockchain & Cryptocurrency

Computer Technology & Software

Consumer Electronics

Electrical Devices

MECHANICAL
& PRODUCTS​

Cleantech

Mechanical Devices

Consumer & Retail Products

Hardware & Tools

Toys & Games

LIFE SCIENCES
& CHEMISTRY​

Biotechnology

Chemical Compounds

Digital Health

Healthcare Products

Pharmaceuticals

BRANDING
& CREATIVE​

Books & Publications

Brand Creation

Luxury Products

Photography & Video

Product Design

call us  206.533.3854